Albany Molecular Research jumps 21% after topping Wall Street’s Q2 estimates
Albany Molecular Research, Inc. (Nasdaq:AMRI) is up 21% after the company, a provider of scientific services, technologies and products, reported a second-quarter profit of $7.7 million, or $0.24 per share, versus a year-earlier profit of $4.6 million, or $0.14 per share. Wall Street expected earnings of $0.10 per share.
Quarterly revenue rose 17% to $57.9 million from $49.4 million a year ago. Wall Street was looking for $51.8 million.
In Wednesday morning trading, AMRI is up 21.11%, or $3.19, to $18.30. For detailed price information and recent news stories about Albany Molecular Research, click AMRI.
About the Author
Reporter Will Atkinson is based in SmallCapInvestor.com's Washington, D.C. bureau.
Read More
(click a star)
Enter comment: